OR WAIT 15 SECS
Clarithromycin oral suspension approved for Ranbaxy Pharmaceuticals
Clarithromycin for Oral Suspension, USP, has been approved by the FDA for Ranbaxy Pharmaceuticals in strengths of 125 mg/5 ml and 250 mg/5 ml. The agent is bioequivalent to Biaxin Granules in the same strengths from Abbott Laboratories. Clarithromycin is indicated for the treatment of mild to moderate infections causes by susceptible microorganisms.